JAGX Jaguar Health, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1585608 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY129.7%
TTM net income YoY18.7%
TTM EPS YoY199.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin81.5%
Operating margin-91.2%
Net margin-121.0%
FCF margin—
EBITDA margin-84.2%
Returns
ROE-252.4%
ROA-79.9%
ROIC (approx.)-230.8%
Asset turnover0.66x
Leverage & solvency
Liabilities / assets42.7%
Debt / equity0.00x
Current ratio1.28x
Interest coverage-21.50x
Cash quality & payout
Operating cash flow / net income0.21x
Accruals ratio-63.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $11.51M | $11.69M |
| Cost of revenue | $3.77M | $1.96M |
| Gross profit | $7.74M | $9.73M |
| R&D expense | $24.97M | $16.54M |
| SG&A expense | $18.64M | $16.33M |
| Operating income | -$45.91M | -$30.83M |
| Interest expense | $67,000 | $231,000 |
| Pretax income | -$54.00M | -$39.25M |
| Income tax | $0 | $0 |
| Net income | -$53.58M | -$38.49M |
| EBITDA | -$43.99M | -$28.93M |
| EPS (basic) | -22.97 | -130.69 |
| EPS (diluted) | -22.97 | -130.69 |
| Weighted avg. shares (diluted) | 2.33M | 294,534 |
| Balance sheet | ||
| Cash & equivalents | $968,000 | $8.00M |
| Receivables | $1.52M | $1.53M |
| Inventory | $8.60M | $10.35M |
| Current assets | $20.34M | $32.20M |
| PP&E, net | $463,000 | $464,000 |
| Intangibles | $16.02M | $18.48M |
| Total assets | $38.32M | $53.42M |
| Current liabilities | $40.65M | $19.70M |
| Total liabilities | $57.01M | $44.45M |
| Shareholders' equity | -$17.29M | $7.29M |
| Cash flow statement | ||
| Operating cash flow | -$23.69M | -$29.38M |
| Capital expenditure | — | $16,000 |
| Free cash flow | — | -$29.40M |
| Investing cash flow | -$41,000 | -$231,000 |
| Financing cash flow | $23.67M | $31.20M |
| Depreciation & amortization | $1.91M | $1.90M |
| Stock-based compensation | $831,000 | $1.64M |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.